Recent Securities Litigations

Iterum Therapeutics plc Ordinary Share (NASDAQ: ITRM)

6 Days left to seek lead plaintiff status.

Company Name:Iterum Therapeutics plc Ordinary Share
Stock Symbol:NASDAQ: ITRM
Class Period Start:11/30/2020
Class Period End (inclusive):07/23/2021
Filing Deadline:10/04/2021

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the sulopenem NDA lacked sufficient data to support approval for the treatment of adult women with uUTIs caused by designated susceptible microorganisms proven or strongly suspected to be non-susceptible to a quinolone; (ii) accordingly, it was unlikely that the FDA would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Iterum Therapeutics plc Ordinary Share (NASDAQ: ITRM) Claim Form

Name(Required)
Address
Consent(Required)
This field is for validation purposes and should be left unchanged.